Pfizer Inc. (NYSE:PFE) Shares Sold by Sompo Asset Management Co. Ltd.

Sompo Asset Management Co. Ltd. decreased its holdings in shares of Pfizer Inc. (NYSE:PFEFree Report) by 13.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 17,360 shares of the biopharmaceutical company’s stock after selling 2,640 shares during the period. Sompo Asset Management Co. Ltd.’s holdings in Pfizer were worth $500,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Stamos Capital Partners L.P. increased its stake in shares of Pfizer by 36.0% during the fourth quarter. Stamos Capital Partners L.P. now owns 378,830 shares of the biopharmaceutical company’s stock worth $10,907,000 after acquiring an additional 100,200 shares during the period. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Pfizer during the 4th quarter worth approximately $233,000. Waterloo Capital L.P. acquired a new position in Pfizer during the fourth quarter worth $1,334,000. Wealth Quarterback LLC raised its position in Pfizer by 15.2% in the fourth quarter. Wealth Quarterback LLC now owns 13,676 shares of the biopharmaceutical company’s stock worth $394,000 after acquiring an additional 1,809 shares in the last quarter. Finally, Sectoral Asset Management Inc. boosted its position in shares of Pfizer by 20.3% during the 4th quarter. Sectoral Asset Management Inc. now owns 189,400 shares of the biopharmaceutical company’s stock worth $5,453,000 after purchasing an additional 32,000 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PFE. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Guggenheim assumed coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Morgan Stanley raised their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $35.86.

Read Our Latest Stock Analysis on Pfizer

Pfizer Trading Down 0.8 %

NYSE PFE traded down $0.22 during mid-day trading on Friday, reaching $28.58. 27,526,200 shares of the stock were exchanged, compared to its average volume of 33,056,490. The business’s fifty day simple moving average is $27.50 and its 200 day simple moving average is $27.88. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The stock has a market capitalization of $161.95 billion, a PE ratio of -476.25, a PEG ratio of 1.13 and a beta of 0.70. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37.

Pfizer (NYSE:PFEGet Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.23 earnings per share. On average, research analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.88%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.